AKT1 and neoplasm: Similar data were reported by Thomas et al (2013) and Toren et al (2015); increased AR transcriptional activity observed using monotherapy with the AKT inhibitor AZD5363 was overcome by combining AZD5363 with ENZ, resulting in synergistic inhibition of cell proliferation and induction of apoptosis, and delayed CRPC tumor growth in vivo.